Latest news
An AI Drug Company Named a Candidate for Dry Macular Degeneration, and the Target Is Undisclosed - Medical DailyMedical Daily · Fri, 07 Aug 2026 11:40:26 GMTInsilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging - Insilico MedicineInsilico Medicine · Thu, 06 Aug 2026 09:47:23 GMTAI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging - EurekAlert!EurekAlert! · Thu, 06 Aug 2026 03:38:35 GMTInsilico Nominates AI-Designed ISM9077, Potential First-in-Class Y Inhibitor, as Preclinical Candidate - Bioengineer.orgBioengineer.org · Thu, 06 Aug 2026 03:03:47 GMTEnveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Ca - BenzingaBenzinga · Wed, 05 Aug 2026 13:30:17 GMTEnveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 - Business WireBusiness Wire · Wed, 05 Aug 2026 12:00:00 GMTNiagen Selects Evotec to Advance Preclinical Development of Oral Small-Molecule Candidate - Contract PharmaContract Pharma · Mon, 03 Aug 2026 21:00:00 GMT